Sofinnova Partners

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Sensorion is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. The company's lead product, SENS-401, is currently in phase II clinical trials aimed at treating sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-111, which is in phase II trials for acute unilateral vestibulopathy, and SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company also collaborates with Cochlear Limited to explore combination therapies for patients with cochlear implants. Founded in 2009, Sensorion is dedicated to conducting research and development to discover drugs that can restore and treat hearing loss, positioning itself as a key player in the field of otology.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Sensorion is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. The company's lead product, SENS-401, is currently in phase II clinical trials aimed at treating sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-111, which is in phase II trials for acute unilateral vestibulopathy, and SENS-300, which is in the pre-clinical stage for addressing inner ear toxicity. The company also collaborates with Cochlear Limited to explore combination therapies for patients with cochlear implants. Founded in 2009, Sensorion is dedicated to conducting research and development to discover drugs that can restore and treat hearing loss, positioning itself as a key player in the field of otology.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass. In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for this revolution in chemicals and biofuels. GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.

Epsilen Bio is developing a transformative therapy known as Epigenetic Silencing to treat human diseases. Epsilen Bio's mission is to develop therapies for patients affected by underserved medical conditions, through stable genomic epigenetic silencing of genes involved in pathological processes. The company was founded in December 2019 and based in Milan, Italy.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Aledia SA specializes in the development and manufacturing of innovative light-emitting diodes (LEDs) utilizing a unique 3D architecture based on gallium-nitride-on-silicon microwires. Founded in 2011 and headquartered in Grenoble, France, with additional subsidiaries in Malacca, Malaysia, and Palo Alto, California, Aledia's technology employs standard 8-inch silicon wafers and existing fabrication processes, allowing for the production of LED chips at a significantly reduced cost compared to traditional planar designs. This technology supports a range of applications, including general lighting, automotive, and display technologies, specifically for mobile and microdisplays used in augmented and virtual reality environments. Aledia's focus on efficient, brighter, and cost-effective displays positions it as a key player in the LED market.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Twenga is an e-commerce platform that specializes in traffic acquisition, price comparison, and enhancing international exposure for online retailers. Founded in September 2006 by Bastien Duclaux and Cedric Anes, the company is headquartered in London and has expanded its operations to France, Germany, and England, employing over 120 people. Twenga serves more than 4,000 clients across 15 countries, providing them with tools to improve advertising performance and optimize their advertising investments. The platform enables users to search for and compare a wide variety of products, including fashion, homeware, games, sports, and gardening items, allowing clients to access a diverse range of products from a single source.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

Aledia SA specializes in the development and manufacturing of innovative light-emitting diodes (LEDs) utilizing a unique 3D architecture based on gallium-nitride-on-silicon microwires. Founded in 2011 and headquartered in Grenoble, France, with additional subsidiaries in Malacca, Malaysia, and Palo Alto, California, Aledia's technology employs standard 8-inch silicon wafers and existing fabrication processes, allowing for the production of LED chips at a significantly reduced cost compared to traditional planar designs. This technology supports a range of applications, including general lighting, automotive, and display technologies, specifically for mobile and microdisplays used in augmented and virtual reality environments. Aledia's focus on efficient, brighter, and cost-effective displays positions it as a key player in the LED market.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

QuesCom S.A. designs and manufactures Internet telecommunication systems. The company provides business communication management portal, GSM gateway, SIM servers, and mobile call servers. It partners with Aastra, Alcatel, Avaya Inc. & Cisco. QuesCom S.A. was founded in 1999 and is headquartered in Sophia Antipolis, France.

Sensitive Object SA specializes in the development of electronic products that enhance touch interface technology across various sectors. Founded in 2003 and headquartered in Boulogne Billancourt, France, the company offers solutions for consumer electronics, computing, outdoor interactive applications, home automation, healthcare, industrial control, and digital advertising. Its product range includes touch screens, peripherals, and control panels, catering to diverse industry needs. Sensitive Object also maintains operations in Paris and Singapore, further expanding its reach in the global market.

EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

blueKiwi Software SA provides enterprise social software for financial firms, high-tech, and professional services agencies. It offers blueKiwi 2009, an enterprise social software for people-centric organizations to create social networks and collaborative environments with partners, customers, and colleagues; and blueKiwi Pro, a social software for small and medium businesses. The company also provides strategic consulting and technical services. It has operations in France and the United Kingdom.

Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.

Neosens SA specializes in the design and development of sensor solutions aimed at monitoring and controlling the quality of water and industrial liquids. The company offers advanced sensors that detect dissolved oxygen and systems for continuous fouling monitoring. Its technologies are applied across various sectors, including cooling systems, heat exchangers, potable and ultra-pure water management, as well as in industries such as food and beverage, pharmaceuticals, pulp and paper, and oil and gas. Founded in 2001 and headquartered in Labege, France, Neosens is committed to providing innovative solutions that enhance the efficiency and safety of liquid management in diverse environmental applications.

Qosmos SA is a provider of network intelligence technology that specializes in deep packet inspection (DPI) for IP traffic classification and analysis. Founded in 2000 and based in Paris, the company develops software and hardware platforms designed to identify and extract information traveling through networks. Its flagship product, ixEngine, includes a comprehensive software development kit offering tools for traffic analysis, protocol recognition, and real-time classification of data flows. Qosmos' solutions support various applications, including lawful interception, network protection, data retention, regulatory compliance, and content-based billing. The company also offers custom development services and professional consulting to assist with the design, deployment, and optimization of network intelligence systems. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates globally and has been a subsidiary of Enea AB since 2016.

Neosens SA specializes in the design and development of sensor solutions aimed at monitoring and controlling the quality of water and industrial liquids. The company offers advanced sensors that detect dissolved oxygen and systems for continuous fouling monitoring. Its technologies are applied across various sectors, including cooling systems, heat exchangers, potable and ultra-pure water management, as well as in industries such as food and beverage, pharmaceuticals, pulp and paper, and oil and gas. Founded in 2001 and headquartered in Labege, France, Neosens is committed to providing innovative solutions that enhance the efficiency and safety of liquid management in diverse environmental applications.

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Streamezzo S.A. develops media mobile products and solutions. Its solutions enable telecom operators, broadcasters, media companies, content providers, and service providers to design, develop, debug, and deploy services on cellular networks. The company’s products include Rich Media Software Suite, which comprise Rich Media Client that enables mobile users to access media services, such as interactive Mobile TV, widgets, portals, and multimedia services; Rich Media Server, an application server that enables to deploy media services; Workbench, an integrated multimedia authoring suite; Service Manager, a back-end solution that enables mobile administrators and marketers to manage and customize media mobile service; and Broadcast, which enables users to deliver mobile TV over broadcast networks. Its solutions comprise Interactive Mobile TV for interactive services; Music Jukebox for over-the-air music downloading; on-device portal for text, image, audio, and video combined information on a mobile portal; Event Microsite for mobile marketing; Dynamic User Interface, which enables to give customers direct access to specific services and applications; and online interactive communication solutions. The company also offers professional services. Streamezzo was founded in 2004 and is based in Paris, France.

VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.

Purple Labs SA specializes in developing mobile Linux software solutions tailored for real-time operating systems (RTOS) and Linux-based mobile devices. The company offers a comprehensive mobile Linux platform and an application suite specifically designed for 3G feature phones, providing essential tools for phone manufacturers to enhance their product offerings. Their flagship product, Purple Magic, is a 3G Linux feature phone that supports video telephony, music playback, high-speed internet browsing, and video streaming. In addition to software solutions, Purple Labs provides application integration, Linux support package customization, hardware design assistance, and product industrialization services. Founded in 2001 and headquartered in Le Bourget du Lac, France, the company has expanded its presence with offices in several regions, including the United Kingdom, the United States, China, South Korea, Taiwan, and Hong Kong. As of 2009, Purple Labs operates as a subsidiary of Myriad Group AG.

Inside Secure, formerly known as INSIDE Contactless S.A., is a French company specializing in open-standard contactless payment and near field communication (NFC) technologies. Founded in 1995 and headquartered in Aix en Provence, it develops a range of semiconductors and software solutions tailored for applications in payment, transit, identity, and access control. Its product offerings include contactless reader interface chips, NFC interface circuits, contactless payment platforms, and memory chips, as well as USB desktop readers and couplers. The company also provides professional services such as application development, pre-personalization, and system integration. Inside Secure serves a diverse clientele, including payment card and mobile phone manufacturers, systems integrators, and financial institutions, and has established a global presence with offices in various countries, including China, Singapore, Poland, South Korea, and the United States.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

blueKiwi Software SA provides enterprise social software for financial firms, high-tech, and professional services agencies. It offers blueKiwi 2009, an enterprise social software for people-centric organizations to create social networks and collaborative environments with partners, customers, and colleagues; and blueKiwi Pro, a social software for small and medium businesses. The company also provides strategic consulting and technical services. It has operations in France and the United Kingdom.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

Qosmos SA is a provider of network intelligence technology that specializes in deep packet inspection (DPI) for IP traffic classification and analysis. Founded in 2000 and based in Paris, the company develops software and hardware platforms designed to identify and extract information traveling through networks. Its flagship product, ixEngine, includes a comprehensive software development kit offering tools for traffic analysis, protocol recognition, and real-time classification of data flows. Qosmos' solutions support various applications, including lawful interception, network protection, data retention, regulatory compliance, and content-based billing. The company also offers custom development services and professional consulting to assist with the design, deployment, and optimization of network intelligence systems. With additional offices in London, Silicon Valley, Tokyo, and Singapore, Qosmos operates globally and has been a subsidiary of Enea AB since 2016.

Varioptic SA specializes in the design and manufacturing of adjustable lens solutions, particularly focusing on electrically controlled optical liquid lenses. Founded in 2002 and based in Lyon, France, the company provides products such as variable focus liquid lenses, autofocus lens modules, and microscope lenses, which cater to diverse sectors including industrial, biometrics, medical, and consumer applications. Varioptic emphasizes research and development to enhance its technology and innovate new products. The company's offerings are distributed through various channels, and it operates as a subsidiary of Invenios France SAS.

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

ABIONYX Pharma SA is a biopharmaceutical company based in Labege, France, specializing in the discovery and development of high-density lipoprotein (HDL) therapies aimed at treating cardiovascular and metabolic diseases. The company is advancing a portfolio of HDL therapies, including CER-001, which is in Phase II clinical trials and is designed to mimic the properties of pre-beta HDL for patients with post-acute coronary syndrome and familial primary hypoalphalipoproteinemia. Additionally, ABIONYX is developing CER-209, a candidate in Phase I trials for metabolic diseases affecting the liver, as well as atherosclerosis and non-alcoholic steato-hepatitis. The company also focuses on innovative therapies for various conditions, including renal and ophthalmological diseases, and possesses a targeted drug delivery platform for oncology applications. Formerly known as Cerenis Therapeutics, ABIONYX Pharma rebranded in August 2019, continuing its commitment to addressing unmet medical needs.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Sefas Innovation was founded in 1991 and has been providing collaborative document composition & production software to Fortune 500 companies for over 15 years. Sefas’ corporate headquarters is in Paris, France, which, along with its UK and US offices, supports over 80 Sefas staff worldwide. Sefas’ Open Print software suite is used by financial services, banking, insurance, utilities, telecoms and public sector organisations for the design, composition and production of B2C documents. These are often complex documents with multiple sources of data; Open Print is unique in its ability to integrate the data from these multiple sources to provide personalized and relevant communications. Increasingly Open Print is being used to redesign mission critical documents so that they can also communicate the latest marketing campaigns and so generate new revenue. The Sefas UK office is based in Bristol and was first opened in 1999. Sefas’ UK clients include Nationwide, EDS Credit Services (Abbey National), HBOS, Inland Revenue, Department of Work & Pensions, Royal & Sun Alliance, RR Donnelley, Bank of Tokyo, DST International and British Telecom who have been using Open Print since (2000).

VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.

Sensitive Object SA specializes in the development of electronic products that enhance touch interface technology across various sectors. Founded in 2003 and headquartered in Boulogne Billancourt, France, the company offers solutions for consumer electronics, computing, outdoor interactive applications, home automation, healthcare, industrial control, and digital advertising. Its product range includes touch screens, peripherals, and control panels, catering to diverse industry needs. Sensitive Object also maintains operations in Paris and Singapore, further expanding its reach in the global market.

Oxxius is a laser design and manufacturing house founded in 2002 to bring disruptive innovations to the market of visible lasers. We develop advanced continuous-wave laser modules targeting numerous applications in bio-photonics, metrology, spectroscopy and other analytics and instrumentation applications, for both research and industry customers. Oxxius is headquartered in western France and located among a major optics and photonics cluster. Oxxius’ products leverage an innovative, patented solid-state laser architecture offering major advances in compactness, reliability and cost of ownership. In addition, this technology enables exceptional spectral and spatial beam characteristics, as well as market-leading power levels. We also offer a broad range of diode laser modules to cover all the wavelength range from UV to near-infrared. Together with bringing outstanding products to the market, Oxxius is committed to offering a world-class level of quality, customer care and service.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Varioptic SA specializes in the design and manufacturing of adjustable lens solutions, particularly focusing on electrically controlled optical liquid lenses. Founded in 2002 and based in Lyon, France, the company provides products such as variable focus liquid lenses, autofocus lens modules, and microscope lenses, which cater to diverse sectors including industrial, biometrics, medical, and consumer applications. Varioptic emphasizes research and development to enhance its technology and innovate new products. The company's offerings are distributed through various channels, and it operates as a subsidiary of Invenios France SAS.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.